


Patent claims:

1. A bisacyloxypropylcysteine conjugate according to formula (I),

5



where R_1 and R_2 can be identical or different and are fatty acid radicals which are bonded by way of the carboxyl group,

$Y = \text{-NH-}, \text{-O-}, \text{-S-}$ or -OCO- ,

R_3 is a covalently, ionically or associatively bonded conjugate radical, in particular a water-soluble and physiologically tolerated, covalently or ionically bonded polymer, in particular covalently bonded polyethylene glycol (polyoxyethylene),


$\text{-(CH}_2\text{-CH}_2\text{-O)}_m\text{-CH}_2\text{-CH}_2\text{-X}$,

where $X = \text{OR}, \text{NR}_2, \text{SR}$ or COOR , and

$R = \text{H}$, benzyl- or C_{1-6} -alkyl, where several radicals R can be identical or different,

a polyoxyethylene-polyoxypropylene copolymer, a dextran, a sugar, a polyvinylpyrrolidone, an alginate, a pectin or a collagen,

and where the polymeric radical R_3 is substituted once, twice or several times by



2. A bisacyloxypropylcysteine conjugate as claimed in claim 1, characterized in that the radicals $R_{1,2}$, which can be identical or different, are C_{7-25} -, preferably

C₈₋₂₂-alkyl, -alkenyl or -alkynyl groups, and the unsaturated positions are preferably in the cis configuration, with the alkyl, alkenyl and alkynyl radicals being branched or unbranched, cyclic or
5 cycloalkyl-substituted radicals.

3. A bisacyloxypropylcysteine conjugate as claimed in claim 1 or 2, characterized in that the molecular weight of a water-soluble polymer radical is selected
10 such that it amounts to from 100 to 30 000 daltons per conjugate molecule.

4. A bisacyloxypropylcysteine conjugate as claimed in one of claims 1 to 3, characterized in that the
15 polyethylene glycol of the radical R₃ has a chain length m of from 5 to 700, preferably of from 100 to 500.

5. A bisacyloxypropylcysteine conjugate as claimed in one of claims 1 to 4, characterized in that the
20 compound is a S-[2,3-bis(acyloxy)-(2S)-propyl]-L-cysteinylcarboxypolyethylene glycol, preferably S-[2,3-bis(palmitoyloxy)-(2S)-propyl]-L-cysteinylcarboxypolyethylene glycol.

25 6. A bisacyloxypropylcysteine conjugate as claimed in one of claims 1 to 4, characterized in that the compound is a S-[2,3-bis(acyloxy)-(2R)-propyl]-L-cysteinylcarboxypolyethylene glycol, preferably S-[2,3-
30 bis(palmitoyloxy)-(2R)-propyl]-L-cysteinylcarboxypolyethylene glycol.

7. A pharmaceutical composition, comprising a bisacyloxypropylcysteine conjugate as claimed in one of
35 claims 1 to 6.

8. The pharmaceutical composition as claimed in claim 7, characterized in that it comprises pharmaceutical

- 19 -

additives or auxiliary substances and, preferably, a pharmaceutically tolerated excipient.

9. The pharmaceutical composition as claimed in claim
5 7 or 8 in the form of a formulation which is suitable for injection, for inhalation or for intranasal or topical administration.

10. The use of the bisacyloxypropylcysteine conjugates
10 as claimed in one of claims 1 to 6, or of the pharmaceutical composition as claimed in claim 7, 8 or 9, for stimulating macrophages, for stimulating antibody synthesis, for defense against infection, for immuno stimulation, particularly in regard to tumors,
15 for preventing and treating septic shock, for wound healing and as an adjuvant for vaccines.